November 13, 2018 06:31 AM ESTUpdated 10:02 AM

On the heels of an Eli Lilly deal, NextCure’s hot hand in I/O attracts a $93M trans-Pacific venture round

John Carroll

Editor & Founder

Last week Eli Lilly showed their faith in NextCure by fronting an immuno-oncology collaboration with $40 million in upfront and equity cash. This week the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

On the heels of an Eli Lilly deal, NextCure’s hot hand in I/O attracts a $93M trans-Pacific venture round

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

On the heels of an Eli Lil­ly deal, NextCure’s hot hand in I/O at­tracts a $93M trans-Pa­cif­ic ven­ture round

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

On the heels of an Eli Lilly deal, NextCure’s hot hand in I/O attracts a $93M trans-Pacific venture round

Applied Therapeutics' rare disease drug gets a CRL

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Novartis to cut 139 jobs in NJ as part of commercial refocus

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway